{"Exaggerate": "The claim exaggerates the increase in insulin prices by stating that they have \"gone THRU THE ROOF\" for patients/taxpayers.", "Understate": "The claim may understate the impact of manufacturer, health plan, and PBM business practices on insulin prices, as suggested by the expert's verdict.", "Lack enough support": "The claim lacks specific evidence or data to support the assertion that insulin prices have increased due to manufacturer, health plan, and PBM business practices.", "Problematic assumption": "The claim assumes that the increase in insulin prices is solely attributed to the practices of manufacturers, health plans, and PBMs, without considering other factors.", "Exist alternative explanation": "The claim does not consider alternative explanations for the increase in insulin prices, such as changes in production costs or market dynamics."}